Petrelintide

What is Petrelintide?

Petrelintide (ZP8396) is a long-acting, acylated human amylin analog developed by Zealand Pharma and partnered with Roche in a March 2025 deal worth up to $5.3 billion — the largest single-asset pharma partnership of 2025. It is a 36-amino-acid dual agonist at the amylin receptor (AMYR) and calcitonin receptor (CTR), engineered for neutral-pH stability to enable once-weekly dosing and co-formulation with other peptides. In Phase 2b ZUPREME-1 (493 randomized, 42 weeks; topline March 2026, published in The Lancet Diabetes & Endocrinology in September 2026), petrelintide produced 7.9–9.8% weight loss at the week-28 primary endpoint vs 1.7% placebo, and weight kept falling to up to 10.7% by week 42 — while achieving placebo-like GI tolerability (single-digit diarrhea/constipation rates; nausea mostly mild and confined to dose escalation). Lower trial withdrawal on drug (8.4%) than placebo (13.6%) suggests patients can actually stay on it long-term. In September 2026 Zealand started the registrational Phase 3 ZUPREME program (about 7,000 participants across three trials). The combination to watch: petrelintide + enicepatide (CT-388, Roche's dual GLP-1/GIP agonist), with a Phase 2 combination trial planned for H2 2026.

What Petrelintide Is Investigated For

Petrelintide (ZP8396) is Zealand Pharma's investigational long-acting amylin analog, partnered with Roche, positioned primarily for chronic weight management — including as a tolerability-focused alternative for patients who cannot tolerate GLP-1 side effects and, prospectively, as a combination partner with CT-388 for enhanced effect. The strongest evidence is the Phase 2b ZUPREME-1 trial (493 randomized, 42 weeks; topline March 2026, full results in The Lancet Diabetes & Endocrinology, September 2026): 7.9–9.8% weight loss across doses at the week-28 primary endpoint versus 1.7% placebo, continuing to up to 10.7% by week 42, with placebo-like GI tolerability (single-digit diarrhea/constipation rates, mostly mild nausea during dose escalation) and notably lower trial withdrawal on drug (8.4%) than placebo (13.6%). Peak weight loss is lower than top-dose semaglutide or tirzepatide, but the tolerability differential is the actual differentiator. The evidence gaps are meaningful: no cardiovascular outcomes trial, long-term safety beyond 42 weeks unknown, no published human body-composition data despite preclinical lean-mass preservation signals, the Phase 3 ZUPREME trials only began in September 2026, and the combination Phase 2 with enicepatide (CT-388) is planned for H2 2026. FDA approval is realistically 2029–2030; petrelintide is not commercially or legally available outside Zealand/Roche-sponsored trials.

History & Discovery

Petrelintide (ZP8396) was developed at Zealand Pharma, the Danish biotech that pioneered cagrilintide before licensing it to Novo Nordisk for the CagriSema combination program. Petrelintide is a structurally distinct successor: a 36-amino-acid acylated human amylin analog re-engineered for chemical stability at neutral pH, which avoids the amyloid fibrillation that has historically plagued amylin therapeutics and enables co-formulation with other peptides. The medicinal-chemistry optimization is described in J Med Chem (2025). After a series of Phase 1 SAD/MAD studies and a Phase 1b multiple-ascending-dose trial, Zealand reported topline Phase 2b ZUPREME-1 data (493 patients, 42 weeks) in March 2026 showing up to 10.7% mean weight loss with placebo-like GI tolerability. The asset's commercial future was reshaped by a March 2025 partnership with Roche worth up to $5.3 billion in upfront, milestone, and royalty payments — the largest single-asset pharma deal of 2025 — positioning petrelintide for monotherapy Phase 3 and a combination Phase 2 with Roche's enicepatide (CT-388) dual GLP-1/GIP agonist. The full ZUPREME-1 results were published in The Lancet Diabetes & Endocrinology in September 2026, and Zealand initiated the registrational Phase 3 ZUPREME program (ZUPREME-3, -4 and -5; about 7,000 participants) on September 22, 2026, with the enicepatide combination Phase 2 planned for H2 2026. In the broader field framing, a March 2026 Peptides review (Bailey, Flatt, Conlon) now groups petrelintide alongside eloralintide, Met-233, and AZD6234 as the second-generation long-acting amylin class — the contemporary cohort of once-weekly amylin analogs displacing pramlintide's mealtime-dosing model and competing for both monotherapy and combination footprint with incretin-class agonists.

How It Works

Amylin is a natural hormone your pancreas releases with insulin after meals — it tells your brain you're full. Petrelintide mimics amylin but lasts much longer, enabling weekly dosing. Unlike GLP-1 drugs, it works through a completely different pathway (amylin/calcitonin receptors instead of GLP-1 receptors), which is why it has a very different side effect profile — much less nausea, especially after the first few weeks.

Petrelintide is a 36-amino-acid acylated human amylin analog engineered for chemical stability at neutral pH (avoiding the amyloid fibrillation problems of native amylin/pramlintide). It acts as a balanced potent agonist at both the amylin receptor (AMYR, a CTR/RAMP heterodimer) and the calcitonin receptor (CTR). Activation in hindbrain structures (area postrema, nucleus tractus solitarius) promotes satiety, restores leptin sensitivity, delays gastric emptying, suppresses postprandial glucagon, and increases energy expenditure. A half-life of about 10 days (Phase 1 SAD/MAD data) supports once-weekly dosing. Phase 2b ZUPREME-1 (493 randomized, 485 dosed, 42 weeks; maintenance doses 1.0–9.0 mg): all 5 dose arms met the week-28 primary endpoint vs placebo (7.9–9.8% vs 1.7%, efficacy estimand; placebo-adjusted differences 6.2–8.1 points), with weight loss reaching up to 10.7% by week 42. Key differentiator: GI tolerability — diarrhea (7% vs 7%) and constipation (7% vs 4%) rates similar to placebo; nausea (20% vs 6%) mostly mild and concentrated in dose escalation; 98% of top-cohort participants reached maintenance dose. Trial withdrawal rate: 8.4% petrelintide vs 13.6% placebo.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Petrelintide:

• 01Cardiovascular outcomes — no CVOT has been conducted; whether petrelintide will produce MACE reduction comparable to semaglutide is not established.
• 02Long-term safety beyond 42 weeks — the Phase 3 ZUPREME trials (started September 2026) will be the first to characterize longer exposure, including any signals related to chronic CTR agonism on bone metabolism; ZUPREME-5 in established cardiovascular disease runs up to 3 years.
• 03Body composition — preclinical DIO rat data suggested preferential fat-mass loss with relative lean mass preservation vs. liraglutide, but human body-composition sub-studies have not been published.
• 04Combination pharmacology with enicepatide (CT-388) — the Phase 2 combination trial planned for H2 2026 will be the first head-to-head test of the petrelintide-plus-incretin combination thesis vs. CagriSema-style combinations.
• 05Performance in real-world adherence conditions outside controlled trials.
• 06Effects in T2D — ZUPREME-2 (NCT06926842) is ongoing with topline expected H2 2026; results will be the first dedicated T2D efficacy and safety data.
• 07Weight-maintenance phase — no data exist on whether weight loss achieved on petrelintide can be maintained with continued dosing past the 42-week observation window, or whether a lower maintenance dose is sufficient after initial loss.
• 08Special populations — efficacy and safety in adolescents, older adults (>75), and patients with significant renal or hepatic impairment have not been characterized; all current trial cohorts are adults with otherwise typical metabolic-trial inclusion criteria.

Forms & Administration

Petrelintide is administered as a once-weekly subcutaneous injection. Phase 2 tested maintenance doses from 1.0 mg to 9.0 mg with 4-week dose escalation; the Phase 3 ZUPREME trials use a 12-week dose-escalation period. Slower escalation improved tolerability significantly vs earlier Phase 1b protocols. Currently only available through clinical trials.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Petrelintide is investigational and not approved by the FDA or any other regulatory authority. The doses cited reflect Phase 2b protocols rather than prescribing guidance.

Timeline of Effects

Common Questions

Who Petrelintide Is NOT For

Drug & Supplement Interactions

Documented drug-interaction data for petrelintide in humans are limited to the trial cohorts and have not been the focus of dedicated interaction studies. The class-level interactions known from pramlintide and other appetite-suppressing peptides serve as the best available proxies. Insulin and insulin secretagogues raise hypoglycemia risk when combined with amylin agonists, and downward titration of those agents at petrelintide initiation is the expected mitigation. Slowed gastric emptying alters absorption rate and peak concentrations of orally administered medications, with particular relevance for narrow-therapeutic-index agents (warfarin, levothyroxine, oral contraceptives, antiepileptics, and oral antibiotics). The planned Phase 2 combination study with enicepatide (CT-388) will eventually characterize dual-agent pharmacology, but until those data are public, combined use outside that trial is inappropriate. Anyone enrolling in a petrelintide trial while taking chronic medication should disclose all concurrent agents to the trial team.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions